MAOB and Parkinson disease: The recommendations of the FORTA list for MAO-B-inhibitors do not comply with current therapy guidelines and distinguish rasagiline and safinamide, which are labeled with C, from selegiline, which is labeled with D. The selective MAO-B-inhibitors are well tolerated and showed few adverse effects in therapy studies on non-geriatric PD patients (Fox et al. 2018).